Arch Therapeutics, Inc. ('Arch' or the 'Company') announced that it has launched a multi-site clinical study (the 'Study') to accelerate payor adoption and differentiate the key benefits of AC5® Advanced Wound System ('AC5') in treating challenging wounds. The Study is expected to enroll and treat up to 60 patients at six sites with a primary end point of wound closure. The launch of the Study completes the near-term commitments listed in the Company's recently announced reimbursement initiative to accelerate sales opportunities for AC5 in doctor's offices and wound care clinics.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.18 USD | +3.51% | +12.38% | -83.70% |
1st Jan change | Capi. | |
---|---|---|
-83.70% | 5.24M | |
+12.07% | 128B | |
-9.04% | 10.65B | |
+0.91% | 8.82B | |
+16.72% | 7.19B | |
+25.15% | 4.99B | |
+7.17% | 3.4B | |
-1.36% | 3.03B | |
-8.73% | 2.14B | |
-10.15% | 2B |
- Stock Market
- Equities
- ARTH Stock
- News Arch Therapeutics, Inc.
- Arch Therapeutics, Inc. Launches Multi-Site Clinical Study for AC5® Advanced Wound System